Does OLAPARIB Cause Myelodysplastic syndrome? 466 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 466 reports of Myelodysplastic syndrome have been filed in association with OLAPARIB (Lynparza). This represents 2.6% of all adverse event reports for OLAPARIB.
466
Reports of Myelodysplastic syndrome with OLAPARIB
2.6%
of all OLAPARIB reports
114
Deaths
136
Hospitalizations
How Dangerous Is Myelodysplastic syndrome From OLAPARIB?
Of the 466 reports, 114 (24.5%) resulted in death, 136 (29.2%) required hospitalization, and 94 (20.2%) were considered life-threatening.
Is Myelodysplastic syndrome Listed in the Official Label?
Yes, Myelodysplastic syndrome is listed as a known adverse reaction in the official FDA drug label for OLAPARIB.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Myelodysplastic syndrome?
CYCLOPHOSPHAMIDE (1,545)
LENALIDOMIDE (1,285)
DOXORUBICIN (1,236)
RITUXIMAB (1,054)
VINCRISTINE (966)
ETOPOSIDE (936)
DEXAMETHASONE (759)
METHOTREXATE (728)
CYTARABINE (715)
CARBOPLATIN (698)
Which OLAPARIB Alternatives Have Lower Myelodysplastic syndrome Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL